司美格鲁肽“保护期”将持续至2027年4月 诺和诺德给中国仿制药上了一课

每日经济新闻
Jun 19

近日,诺和诺德全球总裁兼首席执行官杜麦克(Mike Doustdar)首度明确表态:司美格鲁肽在中国的监管数据保护将持续至2027年第二季度,届时仿制药才能开始合法进入市场。  这并非毫无征兆。早在2026年3月司美格鲁肽在中国的核心化合物专利到期前后,市场上已有诺和诺德司美格鲁肽“保护期延长”的消息流传,但诺和诺德官方始终未予置评,直至杜麦克此次访华期间才首次对外证实。  这一时长超过一年的“...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10